Latest News and Press Releases

Castle presented new data from the first independent validation of the recently published COOG2.1 study by Harbour et al. at ARVO 2025.

Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the first quarter ended March 31, 2025.

Castle Biosciences, Inc. (Nasdaq: CSTL) has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse.

Castle Biosciences will share new data on its TissueCypher test for patients with Barrett’s esophagus at DDW 2025.

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.

Castle announces its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders.

Castle Biosciences will share new data intended to improve the care of patients with cutaneous and uveal melanoma at the AACR Annual Meeting 2025.

Castle will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025.

Castle is supporting key educational programs and initiatives throughout April in recognition of Esophageal Cancer Awareness Month.